GET DAILY SIGNALSQuantum-Si (QSI) Eyes +68% Upside to Reach $2.30 Analyst Target
Key Takeaways
- The $2.30 central target represents the average of three verified analyst price targets: $4.00, $1.90, and $1.00.
- From the latest price near $1.37, that implies roughly 68% upside potential.
- Analyst views span a wide range from $1.00 to $4.00, highlighting significant disagreement on commercial prospects.
- Support comes mainly from the planned Proteus platform launch and a cash balance above $100 million.
- Primary risks include minimal revenue, ongoing cash burn, dilution potential, and Nasdaq listing compliance concerns.
Breaking Down the Analyst Targets
Three individually attributable analyst targets shape this picture. H.C. Wainwright’s Swayampakula Ramakanth holds a Buy rating with a $4.00 target. Alliance Global Partners analyst Scott Henry maintains a Buy at $1.90, reduced from $2.50 in August 2026. Canaccord Genuity’s Kyle Mikson keeps a Hold with a $1.00 target. The arithmetic mean lands at $2.30, with the range stretching from $1.00 to $4.00. One target even sits below the current share price, underscoring the division on the Street. Bullish voices focus on long-term proteomics potential and the upcoming Proteus platform, while cautious ones point to weak near-term revenue and financing needs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where QSI Stands Today
QSI closed near $1.37, for a market capitalization of roughly $300 million. Reaching $2.30 would require an advance of about 68%. Trailing twelve-month revenue totaled only about $1.26 million, with a GAAP net loss of approximately $85 million and EPS around -$0.38. Any meaningful move would hinge less on current results and more on successful execution of the Proteus launch, now targeted for the second quarter of 2027, along with growth in the installed base of Platinum and Platinum Pro instruments. The stock has historically reacted more to sentiment and milestone news than to reported revenue.
Factors That Could Drive Shares Higher
- The Proteus platform could mark a meaningful step forward, and management has targeted roughly $12 million in annual cost savings to extend the runway.
- A partnership with Cell Signaling Technology aims to validate protein sequencing workflows and build scientific credibility.
- Cash of approximately $103.5 million offers operating flexibility through the launch period, though the balance is finite.
- Single-molecule protein sequencing targets a growing proteomics market, and past technical milestones have triggered sharp rallies.
Key Risks to Watch
- Revenue stays minimal, with full-year 2026 guidance near $1.0 million, so the business remains far from self-sustaining.
- A Nasdaq notice in July 2026 flagged the Class A shares falling below the $1.00 minimum bid, with a compliance deadline ahead.
- Continued cash burn and possible equity dilution could weigh on the price even if product progress occurs.
- The stock rests on limited fundamental support, so any delay in the Proteus timeline or weak adoption could shift sentiment quickly.
- Competition in protein analysis tools and broader biotech rotation add further headwinds.
Technical Picture
Over the past 52 weeks, QSI has ranged between roughly $0.69 and $1.81. The $1.00 level serves as both psychological and compliance-related support, while $1.45–$1.50 and the $1.81 52-week high mark key resistance on any push toward $2.30. A sustained move above the prior high would likely be needed before the $2.30 target comes into realistic technical view.
Timeline and Monitoring Points
Analyst targets generally reflect a roughly 12-month horizon. Investors should watch quarterly earnings and revenue, the Proteus launch timeline, cash balances and any financing moves, progress on Nasdaq compliance, and analyst revisions—several targets have already been lowered in 2026 as revenue expectations adjusted. From what I see, tracking these elements closely will clarify whether the average target remains plausible.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to monitor fast-moving names like QSI. The platform uses artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI analysis. For a volatile stock such as this one, the signals can help identify potential entry or exit points and track shifting trends more efficiently than manual review alone. I find it useful for maintaining perspective on positions without constant screen time.
Final Assessment
The $2.30 central target averages three analyst views that range from $1.00 to $4.00, a spread that reflects real uncertainty rather than strong conviction. Achieving that level from around $1.37 would require roughly 68% upside, a substantial move that depends primarily on successful Proteus execution and commercial traction rather than current financial results. Supportive elements include the cash runway, cost discipline, and the proteomics opportunity, while minimal revenue, ongoing losses, dilution risk, and the Nasdaq compliance issue represent meaningful obstacles. The wide disagreement among analysts and the company’s pre-profitability stage suggest the outcome will turn on upcoming milestones more than a steady earnings path.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
QSI's Stochastic Oscillator is remaining in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 96 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for QSI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 23 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 84 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How is a Will Implemented After my Death?
What is a foreign institutional investor?
How can one use ADX as the leading tool to evaluate the strength of a trend?
Best Meat Company Stocks to Buy with Tickeron: A Comprehensive Analysis
[Test] Automate Your Success: Explore Tickeron's Top 10 Stock Trading Robots Now!
General Information
Industry MedicalNursingServices
Advertisement